Fundraising FoxElephant Partners — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
Mellitusmellitusllc.comAug 2023SEC filingmedium confidence
Boston-based developer of an in vitro diagnostic test for diabetes based on the glycated CD59 (GCD59) biomarker.
BiotechBoston, US
Jose Halperin(Director)inJoyce Lonergan(Executive Officer)Michael Chorev(Director)
Board seatChristopher De Souza· per SEC Form D · $750K raise · filed Aug 2023
Co-investorsBroadview VenturesDreamers VC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.